Merck’s Q2 Loss Looms Despite Keytruda’s Growth

Forward-Looking Analysis

Wall Street analysts project a significant contraction in Merck’s profitability for the second quarter of 2026, forecasting a consensus earnings per share (EPS) of -$0.27, a sharp decline from the $2.13 reported in the same quarter of the prior year. This negative outlook represents a year-over-year drop of approximately 112.2%. Revenue is estimated to reach $16.33 billion, reflecting a modest 3.3% increase year-over-year. Despite the expected loss, the consensus EPS estimate has seen a slight upward revision of 1.6% over the past 30 days, suggesting minor analyst optimism regarding cost structures or non-recurring items. Key product forecasts indicate mixed performance within the oncology portfolio: Keytruda sales are expected to grow by 1.3% to $8.06 billion, while international Keytruda sales are projected to rise 3.8% to $3.33 billion. However, Lynparza alliance revenue is anticipated to fall 3.6% to $356.54 million. In the hospital acute care segment, Zerbaxa is expected to see an 8% increase to $79.95 million, and Prevymis is forecast to grow 11.5% to $254.29 million. Conversely, Bridion U.S. sales are expected to drop 20% to $328.80 million, and Janumet U.S. sales are projected to decline 30% to $47.60 million. These divergent trends highlight the complex dynamics driving Merck’s top and bottom lines as it navigates patent cliffs and competitive pressures.

Historical Performance Review

In the first quarter of 2026, Merck reported revenue of $16.29 billion, exceeding the consensus estimate of $15.85 billion and marking a 4.9% year-over-year increase. Despite this top-line growth, the company posted a net loss of $4.24 billion, resulting in a GAAP EPS of -$1.72. Although the reported EPS of -$1.28 beat analyst expectations of -$1.47, the underlying GAAP figure indicates substantial losses, likely driven by one-time charges or restructuring costs. Gross profit stood at $12.09 billion, demonstrating that while sales remain robust, profitability metrics have deteriorated significantly compared to previous positive earnings periods, raising concerns about the sustainability of current margins heading into the second quarter.

Additional News

Merck recently announced the U.S. FDA approval of LIPFENDRA (enlicitide), the first and only once-daily oral PCSK9 inhibitor for reducing LDL-C in adults with hypercholesterolemia. The company also secured FDA approvals for KEYTRUDA, both as monotherapy and in combination with Padcev, for treating muscle-invasive bladder cancer, and for KEYTRUDA with Trodelvy as a first-line treatment for advanced triple-negative breast cancer. Clinical data presented at AIDS 2026 showed that an investigational once-weekly oral HIV regimen maintained virological suppression in adults switching therapy. Additionally, Merck announced initial access plans for Alimatravir, an investigational oral HIV PrEP, and a new agreement with the ADAP Crisis Task Force to improve HIV care access. The company declared a fourth-quarter 2026 dividend of $0.81 per share and plans to hold its Q2 2026 earnings conference call on August 4. Analysts from BMO Capital and Cantor Fitzgerald have maintained Hold ratings, while J.P. Morgan issued a Buy rating.

Summary & Outlook

Merck’s financial health faces near-term headwinds, evidenced by the projected Q2 2026 net loss and significant EPS decline, contrasting with solid revenue growth. While Keytruda continues to drive top-line stability, the expected contraction in other oncology and chronic disease products, alongside broader market pressures, complicates the profit outlook. Regulatory approvals for new cholesterol and cancer therapies provide long-term growth catalysts, but the immediate fiscal picture suggests a transitional period of margin compression. Given the anticipated earnings miss and the challenging macro-environment for pharmaceutical pricing, the outlook remains neutral to slightly bearish for the upcoming quarter, with investors closely watching management’s guidance on cost-cutting measures and Keytruda’s trajectory beyond the patent cliff.